GP41 antigen
US6821723B2 · kind B2 · utility
0Cited by
0References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 2, 2002 |
| Grant date | Nov 23, 2004 |
| Priority date | — |
| Expiry date | Nov 10, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16122
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention comprises novel polypeptide antigens that can be used for therapeutic and prophylactic immunization against HIV-related infections. The polypeptide of the invention mimics the intermediate state of gp41 and is capable of inducing antibodies which neutralize primary isolates of HIV. The invention also comprises compositions comprising the polypeptide and methods of using it.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.